La suplementación de larga duración con atenolol convierte la insaturación de  las membranas mitocondriales de  músculo esquelético y de corazón de ratón  en la  característica   de mamíferos de supervivencia diez veces mayor. Efectos sobre la longevidad by Gomez, Alexia et al.
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   muscle	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   of	   mitochondrial	   membranes	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mice	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   those	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   fold	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   mammals.	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ABSTRACT	  The	   long-­‐term	  effects	  of	   atenolol	   in	  drinking	  water	   throughout	   the	  whole	   lifespan	  (3.3	  years)	  of	  a	  mammal	   (128	  C57BL/6	  male	  mice-­‐SPF)	  were	  studied	   for	   the	   first	  time.	   We	   observed	   beneficial	   aging-­‐related	   changes:	   decreases	   in	   the	   degree	   of	  unsaturation	  of	  mitochondrial	  membranes	  and	  of	  the	  22:6n-­‐3	  fatty	  acid,	  an	  increase	  in	  oleic	  acid,	  as	  well	  as	  decreases	  in	  protein	  oxidation,	  glycoxidation	  and	  lipoxidation	  and	   oxidative	   damage	   in	   mtDNA	   in	   heart	   and	   skeletal	   muscle	   mitochondria.	  However,	  a	  secondary	  effect	  of	  the	  drug	  only	  in	  old	  animals	  was	  detected	  that	  agrees	  with	  recent	  meta-­‐analyses	  in	  human	  patients.	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RESUMEN	  
La	  suplementación	  de	  larga	  duración	  con	  atenolol	  convierte	  la	  insaturación	  de	  	  
las	  membranas	  mitocondriales	  de	  	  músculo	  esquelético	  y	  de	  corazón	  de	  ratón	  	  
en	  la	  	  característica	  	  	  de	  mamíferos	  de	  supervivencia	  diez	  veces	  mayor.	  Efectos	  
sobre	  la	  longevidad	  media	  y	  máxima	  Se	  estudia	  por	  primera	  vez	  el	  efecto	  a	  largo	  plazo	  del	  atenolol	  en	  el	  agua	  de	  bebida	  durante	  toda	  la	  vida	  (3,3	  años)	  de	  un	  mamífero	  (128	  ratones	  C57BL/6	  macho-­‐SPF).	  Observamos	  cambios	  beneficiosos	  relacionados	  con	  el	  envejecimiento:	  descenso	  en	  el	  grado	  de	  insaturación	  de	  las	  membranas	  mitocondriales	  y	  del	  ácido	  graso	  22:6n-­‐3,	  un	   incremento	   del	   ácido	   oleico,	   y	   descenso	   de	   la	   oxidación,	   glicoxidación	   y	  lipoxidación	  de	  proteínas	  y	  daño	  oxidativo	  al	  ADNmt	  en	  mitocondrias	  de	  corazón	  y	  músculo	   esquelético.	   Sin	   embargo,	   detectamos	   un	   efecto	   secundario	   del	   fármaco	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sólo	   en	   animales	   viejos	   que	   coincide	   con	   meta-­‐análisis	   recientes	   en	   pacientes	  humanos.	  
Palabras	  clave:	  Estrés	  oxidativo;	  β-­‐bloqueante;	  Frecuencia	  cardíaca.	  
1.	  INTRODUCTION	  TA	   new	   mammalian	   longevity	   model	   based	   on	   ß-­‐adrenergic	   receptor	  signaling	   interruption	  at	   the	   level	  of	  adenylyl	   cyclase	  has	   reported	  decreased	  bone	  and	  heart	  aging	  and	  increases	  in	  mean	  and	  maximum	  longevity	  in	  AC5	  KO	  (adenylyl	  cyclase	  5	  Knockout)	  mice	  (1).	  We	  have	  previously	  mimicked	  this	  model	  with	  the	  ß-­‐blocker	   atenolol	   in	   short-­‐term	   studies	   (2),	   in	  which	  we	  have	   successfully	  modified	  one	  of	  the	  only	  two	  known	  traits	  correlating	  with	  longevity	  in	  the	  right	  sense:	  the	  low	  degree	  fatty	  acid	  unsaturation	  of	  the	  cellular	  membranes	  of	  the	  tissues	  of	  long-­‐lived	  animals.	  Comparative	  gerontological	  studies	  have	  already	  unveiled	  two	  traits	  that	  can	  explain	  the	  different	  (maximum)	   longevity	  of	  different	  mammals:	   long-­‐lived	  animal	  species	   have	   a	   low	   rate	   of	   mitochondrial	   reactive	   oxygen	   species	   production	  (mitROSp)	  (3,	  4)	  and	  a	  low	  unsaturation	  degree	  of	  membrane	  fatty	  acids	  (5,	  6).	  The	  first	  of	  these	  two	  factors,	  mitROSp,	  can	  be	  experimentally	  decreased	  with	  dietary	   manipulations	   like	   caloric	   restriction	   (7,	   8),	   protein	   restriction	   (9)	   and	  methionine	   restriction	   (10).	   But	   the	   second	   one,	   the	   unsaturation	   degree	   of	  membrane	  fatty	  acids,	   is	  more	  difficult	  to	  modify.	  Increasing	  dietary	  saturated	  fatty	  acids	  have	  unhealthy	   effects	  on	  plasma	   cholesterol	   levels,	   and	   the	   tissue	  global	   FA	  (fatty	  acid)	  unsaturation	  is	  homeostatically	  regulated	  in	  mammalian	  tissues	  through	  control	   of	   gene	   expression	   (11).	   Deficiency	   of	   essential	   PUFAs	   in	   the	   diet	   leads	   to	  strong	   compensatory	   increases	   in	   tissue	   mead	   acid	   (20:3n-­‐9,	   synthesized	   from	  18:1n-­‐9),	   a	   known	   diagnostic	  marker	   of	   essential	   FA	   deficiency,	   or	   to	   increases	   in	  MUFAs	   like	   16:1n-­‐7	   and	   18:1n-­‐9	   (12).	   Homeostatic	   changes	   like	   these	   are	  responsible	  for	  the	  failure	  to	  effectively	  change	  tissue	  DBI	  after	  feeding	  the	  animals	  with	  diets	  differing	  in	  FA	  unsaturation	  (13,	  14).	  	  A	  low	  unsaturation	  degree	  is	  most	  important	  for	  developing	  a	  high	  longevity	  because	  membrane	  fatty	  acid	  double	  bounds	  are	  most	  susceptible	  to	  oxidative	  attack	  due	   to	   two	   reasons:	   a)	   oxygen	   and	   many	   radical	   species	   are	   several	   times	   more	  soluble	   in	   lipid	   membrane	   bilayers	   than	   in	   the	   aqueous	   solution	   (15);	   b)	   the	  sensitivity	  of	  membranes	  to	  lipid	  peroxidation	  increases	  strongly	  as	  a	  function	  of	  the	  number	   of	   double	   bonds	   per	   fatty	   acid	  molecule.	   A	   lower	   total	   number	   of	   double	  bounds	   of	   membrane	   fatty	   acids	   make	   these	   molecules	   more	   resistant	   to	   lipid	  peroxidation.	  Polyunsaturated	   fatty	  acids	   (PUFAs)	  exhibit	   the	  highest	   sensitivity	   to	  ROS	   induced	  oxidative	  damage	  among	  cellular	  macromolecules,	  and	  this	  sensitivity	  increases	   as	   a	   function	   of	   the	   number	   of	   double	   bonds	   per	   fatty	   acid	   molecule	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(16,17).	   The	   negative	   relationship	   between	  membrane	   fatty	   acid	   composition	   and	  longevity	  has	  been	  observed	   in	  all	   the	  animal	  models	   studied,	   including	  mammals,	  birds,	  rodents,	  honeybees,	  mussels,	  and	  humans	  (18,	  19):	  the	  longer	  the	  longevity	  of	  a	  species,	  the	  smaller	  the	  degree	  of	  unsaturation	  of	  the	  FAs	  present	  in	  their	  cellular	  membranes.	  Recently,	  many	  mammalian	  models	  of	  extended	  lifespan	  caused	  single	  gene-­‐mutations	  have	  been	  developed	  (20,	  21).	  Most	  of	  them	  are	  related	  to	  insulin/IGF-­‐1-­‐like	   signaling	   pathways	   (22).	   But	   there	   are	   others	   like	   Agtr1a–/–	   (Angiotensine	   II	  type	   1	   receptors	   targeted	   disrupted)	   mice	   (23)	   and	   AC5KO	   (adenylyl	   cyclase	   5	  Knockout)	  mice	  (1)	  that	  also	  show	  increased	  medium	  and	  maximum	  longevity.	  In	  the	  AC5KO	  model,	  extension	  of	  lifespan	  in	  129/SvJ-­‐C57BL/6	  mice	  has	  been	  obtained	   through	   the	   disruption	   of	   β-­‐adrenergic	   receptor	   signaling	   at	   the	   Type	   5	  adenylyl	  cyclase	  (AC5)	  level	  (1).	  This	  mouse	  showed	  increased	  mean	  and	  maximum	  longevity,	   from	  25	  to	  33	  months,	  and	   from	  33	  to	  37	  months,	   respectively,	  and	  also	  showed	   improvements	   in	   parameters	   related	   to	   bone	   and	   heart	   age-­‐related	  deterioration.	  These	   improvements	  seem	  to	  be	  signaled	  to	  the	  nucleus	  through	  the	  Raf/	   MEK/	   extra	   cellular	   signal-­‐regulated	   kinase	   (p-­‐ERK)	   pathway,	   which	   was	  increased	   in	  heart	  and	  other	   tissues	  of	   the	  AC5KO	  mice,	   together	  with	   increases	   in	  the	  protein	  levels	  of	  MnSOD	  (manganese	  superoxide	  dismutase)	  in	  heart,	  kidney	  and	  brain,	   suggesting	   that	  a	  decrease	   in	  oxidative	  stress	   is	   involved	   in	   the	  mechanisms	  responsible	  for	  the	  aging	  delaying	  effect.	  	  Two	  years	  ago	  we	  discovered	  that	  the	  AC5KO	  model	  can	  be	  mimicked,	  at	  least	  on	  the	  short-­‐term,	  with	  the	  drug	  atenolol,	  by	  treating	  C57BL/6	  normal	  mice	  during	  15	   days	  with	   this	   β1-­‐selective	   blocker	   simply	   added	   to	   drinking	  water	   (2).	   In	   the	  present	  study	  we	  test	  the	  long-­‐term	  effects	  of	  this	  drug	  given	  to	  mice	  in	  their	  drinking	  water	   throughout	   their	  whole	   life,	  using	  128	  male	  mice	  studied	  during	  their	  whole	  life	  span	  (more	  than	  3	  years)	  under	  SPF	  conditions.	  Based	  on	  the	  successful	  results	  of	  our	  previous	  short-­‐term	  studies	  (2),	  we	  hypothesized	  that	  atenolol	  would	  chronically	  decrease	   the	   global	   degree	   of	   unsaturation	   of	   heart	   and	   skeletal	   muscle	   (SKM)	  mitochondrial	  membranes	  of	  mice	   to	   levels	  almost	  similar	   to	   those	  of	   species	  with	  one	   order	   of	  magnitude	   higher	   longevity,	   and	  would	   decrease	   specific	  markers	   of	  oxidative	  stress	  due	   to	   lowered	   in	  vivo	   lipid	  peroxidation.	   In	   this	   investigation	   it	   is	  tested	  for	  the	  first	  time	  whether	  modifying	  one	  of	  the	  only	  two	  known	  correlates	  of	  longevity	   (the	   double	   bond	   index	   of	  mitochondrial	  membranes,	  DBI)	   can	   decrease	  highly	  specific	  markers	  of	  oxidative	  stress	   in	  two	  post-­‐mitotic	   tissues	  of	  a	  mammal	  and	  whether	  it	  can	  modify	  its	  longevity.	  In	   those	   life-­‐long	   atenolol-­‐treated	   animals	   and	   their	   controls	   we	   studied	  physiological	   parameters	   including	   rectal	   temperature,	   basal	  metabolic	   rate,	   heart	  rate	  and	  blood	  pressure	  (at	  18	  and	  35	  months	  of	  age).	  Concerning	  oxidative	  stress,	  we	   measured	   the	   rate	   of	   ROS	   production	   in	   isolated	   functional	   mitochondrial	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(mtROSp),	   mitochondrial	   oxygen	   consumption	   in	   states	   4	   (resting)	   and	   3	  (phosphorylating),	   the	  amounts	  of	   the	  respiratory	  complex	  I,	   II,	   III	  and	  IV	  proteins,	  the	   apoptosis-­‐inducing	   factor	   (AIF)	   which	   is	   also	   required	   for	   the	  assembly/maintenance	   of	   complex	   I	   (24),	   the	   marker	   of	   oxidative	   damage	   to	  mitochondrial	   DNA	   (mtDNA)	   8-­‐oxo-­‐7,8-­‐dihydro-­‐2´-­‐deoxyguanosine	   (8-­‐oxodG),	   five	  different	   specific	   markers	   of	   protein	   oxidative	   modification:	   the	   specific	   protein	  carbonyls	   glutamic	   and	   aminoadipic	   semialdehydes	   (GSA	   and	   AASA)	   indicating	  purely	   protein	   oxidative	   modification,	   the	   protein	   glycoxidation	   markers	  carboxyethyl	   lysine	   (CEL)	   and	   carboxymethyl	   lysine	   (CML),	   and	   the	   protein	  lipoxidation	  markers	  CML	  and	  malondialdehyde	   lysine	   (MDAL).	  We	  also	  measured	  the	   full	   fatty	   acid	   composition	   of	   heart	   and	   SKM	  mitochondrial	  membranes	  which	  allowed	   us	   to	   calculate	   their	   global	   unsaturation	   indexes	   (the	   DBI,	   and	   the	  peroxidizability	   index,	   PI).	   The	   mitochondrial	   biogenesis	   indicators	   peroxisome	  proliferator-­‐activated	   receptor-­‐γ	   coactivator	   (PGC)-­‐1α	   (PGC1),	   the	   mitochondrial	  transcription	   factor	   (TFAM),	   antioxidant	   regulation	   transcription	   factor	   Nrf2	  (Nuclear	   factor	   erythroid	   2-­‐related	   factor	   2),	   and	   the	   p-­‐ERK	   and	   SIRT1	   signalling	  proteins	   related	   to	   longevity	   (25),	   as	  well	   as	   the	  basal	  metabolic	   rate	  of	   the	  whole	  animal,	  the	  rectal	  temperature,	  and	  the	  heart	  rate,	  the	  systolic	  and	  diastolic	  and	  mean	  arterial	  pressures	  were	  also	  measured.	  
2.	  MATERIALS	  AND	  METHODS	  
2.1.	  Animals	  and	  study	  design	  128	  C57BL/6	  male	  mice	  were	  maintained	  in	  a	  separate	  room	  of	  Complutense	  University	  animal	  house	  at	  the	  Faculty	  of	  Medicine	  under	  SPF	  conditions	  during	  their	  whole	   life	   or	   until	   some	   of	   them	   were	   sacrificed	   to	   measure	   physiological	   or	  biochemical	  relevant	  parameters.	  86	  of	  these	  animals	  (43	  Old	  control	  and	  43	  Old-­‐AT-­‐treated)	   were	   used	   only	   to	   obtain	   the	   survival	   curves.	   These	   animals	   were	  maintained	   under	   optimum	   conditions	   (12:12	   (light-­‐dark)	   cycle,	   22°C	   ±	   2°C	   and	  50%	  ±	  10%	  relative	  humidity),	  were	  left	  intact	  during	  their	  whole	  lifespan	  (except	  for	   the	   AT-­‐treatment)	   and	   their	   day	   of	   spontaneous	   death	   was	   recorded.	   The	  treatment	   with	   atenolol	   was	   started	   at	   2	   months	   of	   age.	   A	   separate	   group	   of	   42	  animals	   (21	   controls	   and	   21	   AT-­‐treated)	   was	   established	   at	   the	   beginning	   of	   the	  experiment	   in	   order	   to	   measure	   the	   different	   physiological	   and	   biochemical	  parameters	  when	  reaching	  old	  age	  (after	  16	  months	  of	  experimentation).	  Among	  the	  21	  reporter	  animals	  of	  each	  of	  these	  two	  groups	  (control	  and	  AT-­‐treated),	  7	  animals	  were	   used	   for	   the	   ROS	   and	   oxygen	   consumption	   measurements	   in	   isolated	  mitochondria,	  7	  animals	  were	  used	  for	  the	  measurement	  of	  8-­‐oxodG,	  and	  7	  animals	  were	  used	  to	  assay	  the	  rest	  of	  the	  biochemical	  parameters	  after	  being	  sacrificed	  by	  cervical	  dislocation.	  At	  the	  time	  of	  sacrifice	  these	  reporter	  animals	  had	  18	  months	  of	  age.	   The	   animals	   in	   the	   atenolol	   group	   had	   free	   access	   to	   a	   solution	   of	   0.1	   g/L	   of	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atenolol	  (Sigma,	  A7655)	   in	  drinking	  water.	  The	  diet	  (Panlab,	  Spain)	  was	  offered	  ad	  
libitum	  to	  all	  animals.	  Just	  after	  cervical	  dislocation,	  hearts	  and	  SKM	  (total	  hind	  limb	  muscle)	  were	  immediately	  processed	  to	  isolate	  functional	  mitochondria,	  which	  were	  used	  to	  measure	  mitochondrial	  respiration	  and	  rates	  of	  mtROSp.	  Whole	  hearts	  and	  SKM	  tissue	  samples	  (total	  hind	  limb	  muscle)	  were	  stored	  at	  -­‐80°C	  for	  the	  posterior	  analyses	  of	  the	  rest	  of	  the	  biochemical	  parameters.	  The	  experimental	  animal	  subject	  review	   committee	   from	   the	   Complutense	   University	   of	   Madrid	   approved	   all	   the	  experiments	  in	  C57BL/6	  mice.	  
2.2.	  Physiological	  parameters	  	  Rectal	   temperature	   was	   measured	   using	   a	   rectal	   probe	   (Thermocouple	  thermometer	   model	   8112-­‐20,	   Cole-­‐Parmer	   Instrument	   Company).	   The	  measurements	   were	   performed	   three	   times	   in	   each	  mouse,	   always	   at	   11:00,	   on	  three	  different	  days	  separated	  15	  days	  from	  each	  other,	  during	  the	  last	  2	  months	  of	  experimentation.	  To	  estimate	  the	  basal	  metabolic	  rate,	   individual	  mice	  we	  placed	  inside	   a	   closed-­‐system	   respirometer	   (total	   volume	   2,600	   ml)	   and	   the	   carbon	  dioxide	   produced	   was	   captured	   with	   a	   10%	   KCl	   solution.	   The	   rate	   of	   oxygen	  consumption	   of	   each	   animal	  was	  measured	   at	   rest	  with	   an	   oxygen	   analyzer	   and	  probe	   (Model	   600	   Can	   1691,	   Engineered	   Systems	   &	   Designs)	   at	   23±1°C.	   The	  measurements	  were	   realized	   at	   the	   end	  of	   the	  pharmacological	   treatment.	  Heart	  rate	  and	  blood	  pressure	  were	  measured	  in	  conscious	  mice	  with	  a	  noninvasive	  tail-­‐cuff	   manometry	   system	   (LE5001	   Panlab	   Harvard	   Apparatus).	   Each	   animal	   was	  acclimatized	   for	   at	   least	   three	   practice	   sessions	   in	   the	   three	   consecutive	   weeks	  before	   the	   final	   measurements	   were	   recorded.	   In	   each	   session	   8	   consecutive	  readings	  were	   recorded	   and	   their	   average	  was	   used	   to	   obtain	   systolic,	   diastolic,	  and	  mean	  blood	  pressure.	  These	  measurements	  were	  performed	  during	  the	  last	  2	  months	  of	  experimentation.	  
2.3.	   Isolation	   of	   functional	   mitochondria,	   oxygen	   consumption	   and	   ROS	  
production	  Mitochondria	  were	  obtained	  from	  fresh	  tissue	  by	  the	  procedure	  of	  Mela	  and	  Seitz	  (26)	  with	  modifications.	  After	  checking	  the	  functionality	  and	  phosphorylation	  capacity	  of	  the	  mitochondria	  (high	  respiratory	  control	  ratios)	  the	  rate	  of	  mtROSp	  was	  measured	  by	  the	  fluorometric	  method	  established	  at	  our	  laboratory	  (27).	  The	  rate	  of	  oxygen	  consumption	  of	  heart	  and	  SKM	  mitochondria	  was	  measured	  at	  37°C	  in	  a	  water-­‐thermostatized	  incubation	  chamber	  with	  a	  computer-­‐controlled	  Clark-­‐type	  O2	  electrode	  (Oxygraph,	  Hansatech,	  UK)	  as	  previously	  described	  (28).	  
2.4.	  Oxidative	  damage	  to	  mtDNA	  (8-­‐oxodG)	  Isolation	  of	  mtDNA	  was	  performed	  by	  the	  method	  of	  Latorre	  and	  cols	  (29)	  adapted	   to	   mammals	   (30).	   The	   isolated	   mitochondrial	   DNA	   was	   digested	   to	  deoxynucleoside	  level	  and	  the	  level	  of	  oxidative	  damage	  in	  mtDNA	  was	  estimated	  by	   measuring	   the	   amount	   of	   8-­‐oxo-­‐7,8-­‐dihydro-­‐2’deoxyguanosine	   (8-­‐oxodG)	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referred	   to	   that	   of	   the	   non-­‐oxidized	   base	   (deoxyguanosine,	   dG)	   by	   HPLC-­‐EC	   as	  previously	  described	  (31).	  
2.5.	  Measurement	  of	  mitochondrial	  complexes	  I	  to	  IV,	  AIF,	  SIRT1,	  PGC1,	  TFAM,	  
Nrf2	  and	  ERK	  The	  amounts	  of	  a)	  the	  mitochondrial	  respiratory	  chain	  complexes	  (I	  to	  IV),	  the	   complex	   I	   regulatory	   factor	   AIF,	   the	   mitochondrial	   biogenesis	   protein	  indicators	   SIRT1,	   PGC1,	   and	   TFAM,	   the	   Nrf2-­‐ARE	   pathway	   marker	   Nrf2,	   and	  ERK1/2	   pathway	  marker	   (ERK1/2	   and	   phospho-­‐ERK1/2)	   were	   estimated	   using	  western	  blot	  analyses	  as	  previously	  described	  (2).	  	  
2.6.	  Oxidation-­‐derived	  protein	  damage	  markers	  GSA,	   AASA,	   CML,	   CEL	   and	  MDAL	   were	   determined	   as	   trifluoroacetic	   acid	  methyl	   esters	   (TFAME)	   derivatives	   in	   acid	   hydrolyzed	   delipidated	   and	   reduced	  mitochondrial	   protein	   samples	   by	   GC/MS	   (32)	   using	   a	   HP6890	   Series	   II	   gas	  chromatograph	  (Agilent,	  Barcelona,	  Spain)	  with	  a	  MSD5973A	  Series	  detector	  and	  a	  7683	   Series	   automatic	   injector,	   a	  HP-­‐5MS	   column	   (30-­‐m	   x	   0.25-­‐mm	   x	   0.25-­‐µm),	  and	   the	   described	   temperature	   program	   (32).	   The	   amounts	   of	   product	   were	  expressed	  as	  µmoles	  of	  GSA,	  AASA,	  CML,	  CEL	  or	  MDAL	  per	  mol	  of	  lysine.	  
2.7.	  Fatty	  acid	  analyses	  and	  global	  fatty	  acid	  unsaturation	  indexes	  Fatty	   acids	   from	   mitochondrial	   lipids	   were	   analyzed	   as	   methyl	   esters	  derivatives	   by	   gas	   chromatography	   (GC)	   as	   previously	   described	   (33).	   The	  following	   fatty	   acyl	   indices	   were	   also	   calculated:	   saturated	   fatty	   acids	   (SFA);	  unsaturated	   fatty	   acids	   (UFA);	   monounsaturated	   fatty	   acids	   (MUFA);	  polyunsaturated	  fatty	  acids	  (PUFA)	  from	  n-­‐3	  and	  n-­‐6	  series	  (PUFAn-­‐3	  and	  PUFAn-­‐6);	   and	   average	   chain	   length	   (ACL)=[(Σ%Total14	   x	   14)	   +	   (Σ%	   Total16×16)	   +	  (Σ%Total18×18)	  +	  (Σ%Total20×20)	  +	  (Σ%	  Total22×22)	  +	  (Σ%	  Total24×24)]/100.	  The	  density	   of	   double	   bonds	   in	   the	   membrane	   was	   calculated	   by	   the	   Double	   Bond	  Index,	  DBI	  =	  [(1×Σmol%	  monoenoic)	  +	  (2×Σmol%	  dienoic)	  +	  (3×Σmol%	  trienoic)	  +	  (4×Σmol%	  tetraenoic)	  +	  (5×Σmol%	  pentaenoic)	  +	  (6×Σmol%	  hexaenoic)].	  Finally,	  the	  membrane	  susceptibility	  to	  peroxidation	  was	  calculated	  by	  the	  Peroxidizability	  Index,	  PI=	  [(0.025×Σmol%	  monoenoic)	  +	  (1×Σmol%	  dienoic)	  +	  (2×Σmol%	  trienoic)	  +	  (4×Σmol%	  tetraenoic)	  +	  (6×Σmol%	  pentaenoic)	  +	  (8×Σmol%	  hexaenoic)].	  	  
2.8.	  Statistics	  Values	   were	   expressed	   as	   means	   ±	   standard	   error	   of	   the	   mean	   (SEM).	  Comparisons	  between	  groups	  were	  analyzed	  by	  ANOVA	  followed	  by	  DMS	  tests	  for	  paired	   groups	   and	   Student-­‐t	   test.	   The	   survival	   curve	  was	   performed	   by	   Kaplan-­‐Meier	   in	   Statgraphics,	   and	  mean	   and	  maximum	   (last	   10%	   surviving	   individuals)	  life	   span	   values	   were	   analysed	   by	   the	   log	   rank	   test.	   The	   minimum	   level	   of	  statistical	  significance	  was	  set	  at	  P<	  0.05	  in	  all	  the	  analyses.	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3.	  RESULTS	  The	  mean	   body	   weight	   of	   the	   animals	   did	   not	   show	   significant	   differences	  between	   the	   two	   experimental	   groups	   at	   the	   beginning	   neither	   at	   the	   end	   of	   the	  experiment	  (results	  not	  shown).	  	  No	   significant	   differences	   were	   observed	   between	   atenolol	   and	   control	  animals	   for	   rectal	   temperature	   (35.24±0.1	   °C	   in	  Old	  Controls	   and	  35.51±0.2	   in	  Old	  AT)	  or	  basal	  metabolic	  rate	  (3.44±0.28	  mlO2/g	  hr	  in	  Old	  Controls	  and	  3.32±0.3	  in	  Old	  AT).	   Neither	   the	   basal	   rates	   of	   mtROSp	   of	   heart	   mitochondria	   (with	  glutamate/malate	   and	   with	   succinate+rotenone)	   nor	   the	   maximal	   ones	   (with	  glutamate/malate+rotenone)	   were	   significantly	   modified	   by	   atenolol	   treatment	  (results	  not	  shown).	  In	  the	  case	  of	  SKM	  mitochondria	  only	  a	  significant	  decrease	  with	  succinate+rotenone	  (from	  0.92±0.07	  in	  Old	  Controls	  to	  0.75±0.05	  in	  Old	  AT	  P<0.05)	  was	  detected.	  No	  significant	  differences	  in	  mitochondrial	  oxygen	  consumption	  were	  observed	  either,	  except	  for	  significant	  decreases	  only	  in	  the	  case	  of	  state	  3	  respiration	  in	  heart	  with	  both	  complex	  I	  –linked	  (glutamate/malate:	  222.7±30.0	  nanomoles	  of	  O2	  /min	  mg	  mitochondrial	  protein	  in	  Old	  Control	  and	  131.8±8.7	  in	  Old	  AT,	  P<0.05)	  and	  complex	   II-­‐linked	   (succinate+rotenone:	   270.4±21.2	   nanomoles	   of	   O2	   /min	   mg	  mitochondrial	  protein	  in	  Old	  Control	  and	  201.4±8.8	  in	  Old	  AT)	  respiration.	  Concerning	   respiratory	   complexes	   and	   AIF,	   no	   significant	   differences	   were	  observed	   for	   any	   parameter	   in	   the	   case	   of	   SKM	   (results	   not	   shown).	   In	   heart	  mitochondria,	   only	   the	   amount	   of	   complex	   II	   increased	   from	   104.0±5.8	   in	   Old	  Controls	   to	   135.6±12.6	   in	   Old	   AT	   (P<0.05;	   ratio	   of	   complex	   II/porin	   in	   arbitrary	  units),	   the	   rest	   of	   the	   parameters	   not	   showing	   significant	   variations	   (results	   not	  shown).	  	   Atenolol	   treatment	   decreased	   the	   highly	   unsaturated	   22:6n-­‐3	   FA	   and	  increased	   the	  much	   less	   unsaturated	   18:1n-­‐9	   in	   heart	   and	   SKM	   (Figure	   1).	   The	  decrease	   in	   22:6n-­‐3	  was	   of	   23%	   in	   heart	   and	   of	   38%	   in	   SKM.	   Besides,	   the	   ratio	  22:6n-­‐3/24:6n-­‐3,	   an	   index	   of	   the	   final	   steps	   of	   n-­‐3	   synthesis	   through	   β-­‐peroxisomal	  lipoxidation	  (Figure	  2)	  decreased	  in	  both	  tissues	  in	  the	  atenolol	  group	  (Figure	  1;	  by	  37%	  in	  SKM	  and	  by	  46%	  in	  heart).	  	  	   AT	   animals	   showed	  higher	  18:1n-­‐9	   (large	   increase),	   20:4n-­‐6	   and	  24:5n-­‐3,	  and	  lower	  14:0,	  20:3n-­‐6	  and	  especially	  22:6n-­‐3	  than	  controls	  (18:1n-­‐9	  and	  22:6n-­‐3	  values	  are	  shown	  in	  Figure	  1	  while	  the	  other	  FAs,	  which	  were	  measured,	  are	  not	  shown).	  In	  SKM,	  AT	  animals	  showed	  higher	  18:1n-­‐9	  and	  20:2n-­‐6,	  and	  lower	  22:6n-­‐3	  (large	  decrease)	  than	  controls.	  The	  increase	  in	  18:1n-­‐9	  was	  of	  30%	  in	  SKM	  and	  of	  56%	   in	   heart.	   As	   a	   result	   of	   those	   changes,	   the	   global	   indexes	   of	   fatty	   acid	  unsaturation	  DBI	  and	  PI	  were	  strongly	  decreased	  by	  the	  atenolol	  treatment	  in	  both	  kinds	  of	  mitochondria	  (Figure	  3).	  The	  DBI	  decreased	  by	  22%	  in	  SKM	  and	  by	  11%	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in	  heart	  mitochondria,	  while	  the	  PI	  was	  decreased	  by	  31%	  in	  SKM	  and	  by	  17%	  in	  heart	  mitochondria.	  
	  
Figure	  1.-­‐	  Oleic	  (18:1n-­‐9),	  Docosahexanoic	  (22:6n-­‐3)	  and	  Peroxisomal	  Beta-­‐Oxidation	  (22:6/24:6	  ratio)	  from	  control	  and	  atenolol	  treated	  mice.	  Values	  are	  means	  ±	  SEM	  from	  5-­‐6	  (heart)	  or	  6	  (SKM)	  different	   animals	   and	   are	   expressed	   as	   percentage	   of	   those	   in	   the	   controls	   for	   each	   parameter.	  Control	  values:	  12.85±0.76	  (18:1n-­‐9,	  heart);	  28.03±1.01	  (22:6n-­‐3,	  heart);	  187.94±19.46	  (22:6/24.6,	  heart);	   16.39±0.47	   (18:1n-­‐9,	   SKM);	   21.29±0.53	   (22:6n-­‐3,	   SKM);	   103.44±10.32	   (22:6/24.6,	   SKM).	  Asterisks	  represent	  significant	  differences	  between	  the	  control	  and	  the	  atenolol	  group.	  *	  P<0.05;	  **	  P<0.01;	  ***	  P<0.001.	  
Figure	   2.-­‐	  Metabolic	  pathway	   from	   fatty	  acids	  of	   the	  n-­‐3	   serie.	  The	  name	  of	   the	  mouse	  enzymes	  likely	   to	   contribute	   to	   elongation	   (ELOVL	   2	   and	   5)	   and	   desaturation	   (Stearoyl-­‐CoA	   desaturase,	  SCDs)	  steps	  are	  indicated	  in	  these	  pathway.	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Figure	   3.-­‐	   Double	   bond	   index	   (DBI)	   and	   peroxidizability	   index	   (PI)	   in	   heart	   (A)	   and	   SKM	   (B)	  mitochondrial	   fatty	  acids	  from	  control	  and	  atenolol	  treated	  mice.	  Values	  are	  means	  ±	  SEM	  from	  6	  (heart)	  or	  5-­‐6	  (SKM)	  different	  animals	  and	  are	  expressed	  as	  percentage	  of	  those	  in	  the	  controls	  for	  each	   parameter.	   Control	   values:	   232.60±5.90	   (DBI,	   heart);	   268.39±8.02	   (PI,	   heart);	   203.91±3.38	  (DBI,	   SKM);	   217.36±4.52	   (PI,	   SKM).	   For	   calculation	   of	   DBI	   and	   PI	   values	   see	   the	   Materials	   and	  Methods	  section.	  Asterisks	   represent	  significant	  differences	  between	   the	  control	  and	   the	  atenolol	  group.	  *	  P<0.05;	  **	  P<0.01;	  ***	  P<0.001.	  	   Oxidative	  damage	  in	  heart	  mtDNA	  significantly	  decreased	  from	  20.65±3.81	  8-­‐oxodG/105dG	  in	  Old	  Controls	  to	  10.07±1.37	  in	  Old	  AT	  (P<0.05),	  whereas	  in	  the	  case	  of	   SKM	   the	   trend	   to	  decrease	   in	   the	  AT	  group	  did	  not	   reach	   statistical	   significance	  (results	  not	  shown).	  Protein	   oxidation,	   glycoxidation	   and	   lipoxidation	   markers	   are	   shown	   in	  Figures	   4	   and	  5.	   In	   heart	  mitochondria	   all	   the	   five	  markers	  measured,	   GSA,	  AASA,	  CEL,	  CML	  and	  MDAL,	  were	  significantly	  lower	  in	  Old	  AT-­‐animals	  than	  in	  Old	  controls	  (Figure	   4).	   In	   SKM	   mitochondria	   the	   values	   of	   GSA,	   AASA,	   CML	   and	   MDAL	   were	  significantly	   lower	   in	   the	   atenolol	   treated	   animals.	   These	   decreases	   were	   rather	  strong	  and	  ranged	  from	  31%	  to	  51%	  depending	  on	  the	  parameter	  measured	  and	  the	  tissue	   considered.	  Only	   in	   the	   case	  of	  CEL	   the	  decrease	   shown	  by	  AT	  compared	   to	  controls	   did	   not	   reach	   statistical	   significance	   (Figure	   5).	   Concerning	  mitochondrial	  biogenesis,	   antioxidant	   factors	   and	   signaling	   proteins,	   SIRT1	   increased	   and	   Nrf2	  decreased	  in	  Old	  AT	  in	  heart	  (P<0.05)	  but	  not	  in	  SKM	  mitochondria.	  TFAM	  decreased	  in	  Old	  AT	  in	  SKM	  (P<0.05)	  but	  not	  in	  heart	  mitochondria,	  while	  PGC1	  did	  not	  show	  significant	  changes	  in	  any	  organ	  (results	  not	  shown).	  The	  ratio	  of	  the	  phosphorylated	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to	   total	   ERK	   (p-­‐ERK/total	   ERK)	   showed	   significantly	   higher	   values	   in	   the	   atenolol	  than	  in	  the	  control	  group	  (Figure	  6).	  	  
	  
Figure	  4.-­‐	  Protein	  oxidation,	  glycoxidation	  and	  lipoxidation	  indicators	  in	  heart	  mitochondria	  from	  control	   and	   atenolol	   treated	   mice.	   Values	   are	   means	   ±	   SEM	   from	   6	   different	   animals	   and	   are	  expressed	   as	   percentage	   of	   those	   in	   the	   controls	   for	   each	   protein	   modification	   marker.	   Control	  values:	   3,817±128	   (glutamic	   semialdehyde,	   GSA);	   434±37	   (AASA,	   aminoadipic	   semialdehyde,	  AASA);	   557±41	   (carboxyethyl-­‐lysine,	   CEL);	   1038±77	   (carboxymethyl-­‐lysine,	   CML);	   16295±364	  (malondialdehyde-­‐lysine,	   MDAL).	   Units:	   µmol/mol	   lysine.	   Asterisks	   represent	   significant	  differences	  between	  the	  control	  and	  the	  atenolol	  group.	  **	  P<0.01;	  ***	  P<0.001.	  	  	   No	  significant	  differences	   in	  heart	   rate,	  or	   the	  systolic,	  mean	  and	  diastolic	  arterial	   blood	   pressures	   were	   observed	   at	   18	   months	   of	   age	   (Figure	   7A).	   In	  contrast,	   the	   heart	   rate	   measured	   at	   35	   months	   of	   age	   was	   significantly	   and	  strongly	  decreased	   in	   the	  atenolol	  group	  (Figure	  7B),	  whereas	   the	  systolic,	  mean	  and	  diastolic	  arterial	  pressures	  trends	  to	  decreased	  values	  did	  not	  reach	  statistical	  significance	  (Figure	  7B).	  Finally,	  the	  Kaplan	  Meier´s	  survival	  curve	  (Figure	  8)	  showed	  a	  similar	  mean	  life	  span	  (50%	  survival)	  and	  a	  lower	  maximum	  (at	  10%	  survival)	  longevity	  in	  the	  atenolol	   group	   only	   at	   old	   age,	   the	   difference	   in	   survival	   starting	   only	   after	   28	  months	  of	  age.	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Figure	  5.-­‐	  Protein	  oxidation,	  glycoxidation	  and	  lipoxidation	  indicators	   in	  SKM	  mitochondria	  from	  control	   and	   atenolol	   treated	   mice.	   Values	   are	   means	   ±	   SEM	   from	   6	   different	   animals	   and	   are	  expressed	   as	   percentage	   of	   those	   in	   the	   controls	   for	   each	   protein	   modification	   marker.	   Control	  values:	   4,415±272	   (glutamic	   semialdehyde,	   GSA);	   463±24	   (AASA,	   aminoadipic	   semialdehyde,	  AASA);	   380±25	   (carboxyethyl-­‐lysine,	   CEL);	   770±48	   (carboxymethyl-­‐lysine,	   CML);	   632±65	  (malondialdehyde-­‐lysine,	   MDAL).	   Units:	   µmol/mol	   lysine.	   Asterisks	   represent	   significant	  differences	  between	  the	  control	  and	  the	  atenolol	  group.	  **	  P<0.01;	  ***	  P<0.001.	  	  
	  Figure	  6.-­‐	  Ratio	  p-­‐ERK/total	  ERK.	  Ratio	  of	  phosphorylated	  versus	  total	  ERK	  (nonphosphorylated)	  (p-­‐ERK/ERK);	  ERK	  represents	  the	  sum	  of	  the	  44-­‐kD	  and	  the	  42-­‐kD	  ERK	  proteins.	  Values	  presented	  are	   means_standard	   error	   of	   the	   mean	   (SEM)	   from	   n=4	   different	   animals	   per	   group	   over	  immunoreactivity	  in	  control	  values.	  Asterisk	  represents	  significant	  differences	  compared	  to	  values	  of	  untreated	  animals.	  (*)	  p<0.05.	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Figure	  7.-­‐	  Blood	  pressure	  parameters	  (B)	  and	  heart	  rate	  (A)	  measured	  at	  18	  and	  35	  months.	  Values	  are	  means	  ±	  SEM	  from	  7	  different	  animals.	  Blood	  pressure	  units:	  mm	  of	  Hg	  Heart	  rate	  units:	  bits	  per	  min.	  (***)	  p<0.001.	  	  	  
	  
Figure	   8.-­‐	   Kaplan-­‐Meier	   survival	   curve	   for	   control	   and	  atenolol-­‐treated	  C57BL6	  male	  mice.	   (log-­‐rank	  χ2=	  4.40401,	  P=	  0.0358512)	  life	  span	  extension	  in	  control	  mice	  (n=	  43	  for	  control	  and	  n=	  43	  for	  atenolol	  mice).	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4.	  DISCUSSION	  In	   the	   present	   work	   we	   comprehensively	   studied,	   for	   the	   first	   time,	   the	  chronic	  effect	  of	   the	  β-­‐1	  blocker	  atenolol	  on	  various	  metabolic	  and	  oxidative	  stress	  parameters	   during	   the	  whole	   life	   span	  of	   a	   sufficiently	   large	  population	  of	   healthy	  mice.	   After	  16	  months	  of	  continuous	  atenolol	  treatment,	  we	  observed	  quantitatively	  important	   decreases	   in	   the	   fatty	   acid	   unsaturation	   degree	   of	   mitochondrial	  membranes,	   as	   well	   as	   in	   protein	   oxidation,	   lipoxidation	   and	   glycoxidation	   in	  mitochondria	  from	  the	  two	  tissues	  studied:	  heart	  and	  SKM.	  This	  agrees	  with	  similar	  changes	  observed	  after	  15	  days	  of	  treatment	  with	  the	  same	  dose	  of	  atenolol	  in	  mouse	  heart	   (2),	   indicating	   that	   the	   most	   important	   capacity	   of	   this	   drug	   to	   lower	   this	  parameter	  can	  be	  maintained	  at	  least	  during	  most	  of	  the	  lifespan	  of	  the	  animals.	  These	   results	   indicate	   that	   blocking	   of	   the	   β1-­‐adrenergic	   signaling	   pathway	  improves	  one	  of	  the	  only	  two	  known	  parameters	  which	  link	  longevity	  and	  oxidative	  stress,	   the	  DBI	  and	  PI	  (reviewed	  in	  34,	  35).	  Strikingly,	   the	  potency	  of	  atenolol	   is	  so	  great	  that	  it	  can	  decrease	  the	  DBI	  of	  mitochondrial	  membranes	  from	  that	  of	  a	  mouse	  to	  that	  typical	  of	  a	  mammal	  of	  around	  40	  years	  in	  longevity	  (2),	  taking	  into	  account	  the	   known	   relationship	   between	   membrane	   FA	   unsaturation	   and	   mammalian	  longevity	  (34),	  also	  in	  relation	  to	  the	  extended	  life-­‐span	  of	  the	  AC5KO	  mice	  (1).	  In	   our	   longevity	   experiment,	   the	   atenolol	   treatment	   did	   not	   modify	   body	  weight,	   heart	   and	   SKM	  organ	  weight,	   or	   food	   intake,	   this	   ruling	   out	   the	  possibility	  that	   the	   observed	   changes	   could	   be	   secondary	   effects	   of	   caloric	   restriction.	   In	   our	  study,	   atenolol	   treatment	  did	  not	   change	  either	   complex	   I	   or	   III	  mtROS	  generation	  rate	  neither	  with	  glutamate/malate	  nor	  with	  pyruvate/malate	  as	  substrates	  or	  with	  the	   supplemented	   complex	   I	   and	   III	   specific	   inhibitors	   rotenone	   or	   antimicyn	   A.	  These	   results	  agree	  with	   those	   from	  our	   short-­‐term	  study	   in	   the	  heart	  of	   atenolol-­‐treated	   C57BL/6	  mice	   (2),	   and	   are	   in	   contrast	   to	   dietary,	   protein	   and	  methionine	  restriction	  models	  in	  which	  mtROSp	  decreases	  at	  complex	  I	  (36).	  All	  of	  these	  dietary	  manipulations	   increase	   longevity	   and	   decrease	  mtROSp	  without	   changing	   the	   DBI	  and	   PI	   (37).	   However,	   the	   β-­‐adrenergic	   signalling	   blockade	   seems	   to	   decrease	   the	  other	   longevity-­‐related	   trait	   (lowers	   the	   DBI	   and	   PI)	   without	   changing	   mtROSp.	  Therefore,	   these	   two	   manipulations,	   the	   dietary	   restrictions	   and	   the	   atenolol	  treatment,	  seem	  to	  be	  complementary.	  Supporting	   that	   general	   idea,	   long-­‐term	   treatment	   with	   atenolol	   did	   not	  change	  any	  of	  the	  mitochondrial	  respiratory	  chain	  complexes	  except	  for	  the	  increase	  in	  complex	  II	  (70	  KDa	  subunit,	  Flavoprotein)	  in	  heart	  mitochondria,	  mtROSp	  and	  the	  level	  of	  8-­‐oxodG	   in	  mtDNA	  (which	   indicates	   the	  balance	  between	  mtDNA	  oxidative	  damage	  and	  repair).	  mtROSp	  and	  8-­‐oxodG	  in	  mtDNA	  usually	  change	  together	  and	  in	  similar	  direction	  in	  different	  models	  of	  dietary	  restriction	  studied	  and	  both	  are	  lower	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in	   long-­‐lived	   compared	   to	   short-­‐lived	   animal	   species	   (38).	   In	   the	   present	   study,	  although	  the	  atenolol	   treatment	  did	  not	  decrease	  mtROSp,	   the	  oxidative	  damage	  to	  mtDNA	   was	   significantly	   lower	   in	   heart	   mitochondria	   in	   the	   atenolol	   group	   and	  tended	   to	   be	   lower	   (non	   significant	   trend)	   in	   SKM	   mitochondria.	   Rarely,	   but	  sometimes,	  the	  changes	  in	  both	  parameters	  (mtROSp	  and	  mtDNA	  oxidative	  damage)	  in	   longevity	  modifying	   experiments	   have	   been	   apparently	   dissociated	   (39).	  Maybe	  the	  longest	  time	  of	  drug	  exposure	  of	  the	  present	  study	  can	  induce	  an	  increase	  in	  the	  mitochondrial	   mtDNA	   repair	   systems,	   resulting	   in	   the	   decreased	   8-­‐oxodG	   levels	  observed.	  There	   is	   a	   systematic	   negative	   relationship	   between	   tissue	  membrane	   fatty	  acid	   unsaturation	   and	   longevity	   in	   all	   mammals	   studied	   to	   date	   (35,	   40).	  Extraordinarily	   long-­‐lived	   animals	   like	   birds	   (41,	   42),	   naked	   mole	   rats	   (43),	   the	  echidna	  (44)	  and	  queen	  honey	  bees	  (35)	  also	  show	  a	  common	  trait:	  they	  also	  have	  a	  low	   fatty	   acid	   unsaturation	   degree	   in	   their	   tissue	   cellular	  membranes.	   This	  makes	  their	   membranes	   more	   resistant	   to	   lipid	   peroxidation,	   since	   the	   sensitivity	   of	  membrane	  lipids	  to	  lipid	  peroxidation	  increases	  in	  an	  exponential	  way	  as	  a	  function	  of	  the	  number	  of	  double	  bonds	  per	  fatty	  acid	  molecule	  (17).	  This	  also	  occurs	  in	  long-­‐lived	   wild-­‐derived	   strains	   of	   mice	   when	   compared	   to	   genetically	   heterogeneous	  laboratory	  mice	  (45).	  In	  our	  study,	  the	  atenolol	  treatment	  significantly	  decreased	  the	  DBI	  in	  heart	  and	  SKM	  (11%	  and	  22.35%	  respectively	  total	  decrease)	  and	  the	  PI	  also	  in	  both	  tissues	  (16.76%	  and	  30.66%	  respectively	  total	  decrease).	  These	  results	  are	  in	  general	   agreement	   with	   our	   previous	   study	   in	   C57BL/6	   mice	   heart,	   in	   which	   the	  decrease	  was	  40%	   for	   the	  PI	   and	  30%	   for	   the	  DBI	   respectively,	   although	   this	  was	  observed,	  at	  variance	  with	  the	  present	  investigation,	  in	  total	  heart	  tissue	  instead	  of	  in	  heart	  and	  SKM	  mitochondria	  (2).	  	  The	   longevity-­‐related	   decrease	   in	   global	   FA	   unsaturation	   is	   due	   to	   a	  redistribution	   between	   the	   type	   of	   PUFAs	   present	   from	   the	   highly	   unsaturated	  docosahexaenoic	  (22:6n-­‐3)	  and	  sometimes	  arachidonic	  (20:4n-­‐6)	  acids	  in	  short-­‐lived	  animal	   species	   to	   the	   less	   unsaturated	   linoleic	   acid	   (18:2n-­‐6)	   and,	   in	   some	   cases,	  linolenic	  acid	  (18:3n-­‐3)	  in	  the	  long-­‐lived	  ones	  at	  mitochondrial	  and	  tissue	  levels	  (40).	  Among	  these	  FAs,	  the	  one	  contributing	  most	  to	  the	  low	  global	  fatty	  acid	  unsaturation	  of	   long-­‐lived	  animals	   is	  22:6n-­‐3.	  This	  agrees	  strikingly	  well	  with	  our	  results,	  which	  show	  an	  important	  decrease	  in	  the	  amount	  of	  docosahexahenoic	  acid	  (22:6n-­‐3)	  in	  the	  atenolol	  treated	  animals	  in	  mitochondria	  from	  both	  tissues.	  It	  is	  also	  interesting	  that	  the	   fatty	   acid	   showing	   quantitatively	   more	   important	   increases	   in	   long	   lived	  mammals	   in	   general	   is	   18:2n-­‐6,	   but	   in	   the	   bird	   case,	   important	   increases	   occurs	  frequently	  for	  the	  monounsaturated	  oleic	  acid	  (18:1n-­‐9)	  in	  long-­‐lived	  species	  (46),	  a	  FA	  with	  well	  known	  beneficial	  effects	   in	  many	  nutritional	   studies,	  and	   this	  FA	  also	  increases	  in	  our	  case	  in	  the	  long-­‐life	  atenolol-­‐treated	  group.	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Docosahexahenoic	  acid	  (22:6n-­‐3)	  has	  six	  double	  bonds	  and	  consequently	  has	  five	  bis-­‐allylic	  hydrogens	  per	  chain,	  and	  is	  320-­‐times	  more	  susceptible	  to	  ROS	  attack	  than	  oleic	  acid	  (18:1n-­‐9),	  which	  is	  consistent	  with	  the	  strong	  decrease	  in	  secondary	  protein	  lipoperoxidation	  observed	  (lower	  MDAL	  and	  CML	  in	  AT-­‐treated	  animals).	  In	  our	  case,	  a	  most	  relevant	  factor	  that	  contributed	  to	  decrease	  the	  DBI	  and	  PI	  seems	  to	  be	   the	   strong	   decrease	   in	   β-­‐peroxisomal	   lipoxidation	   (estimated	   as	   the	   22:6n-­‐3/24:6n-­‐3	  ratio)	  in	  the	  atenolol	  group.	  The	  main	  function	  of	  this	  process	  seems	  to	  be	  the	   partial	   degradation	   of	   very-­‐long	   chain	   fatty	   acids,	   producing	   chain-­‐shortened	  acyl-­‐CoAs,	   acetyl-­‐CoA	   and	  NADH,	  which	  may	   exit	   from	  peroxisomes	   via	   pores	   that	  permit	  the	  influx	  of	  substrates	  and	  efflux	  of	  products	  of	  β-­‐oxidation.	  These	  substrates	  go	  back	  to	  the	  mitochondria	  to	  complete	  the	  fatty	  acid	  oxidation	  process	  (47).	  The	  decrease	   in	  DBI	  and	  PI	  confers	  higher	  resistance	  of	  membranes	  to	   lipid	  peroxidation	   and	   lowers	   lipoxidation-­‐dependent	   damage	   to	   macromolecules,	   like	  proteins,	   and	   (likely)	   mtDNA.	   The	   long-­‐term	   atenolol	   treatment	   was	   able	   to	   very	  strongly	  and	  significantly	  decrease	  protein	  oxidation	  (GSA	  and	  AASA),	  glycoxidation	  (CEL	  and	  CML)	  and	  lipoxidation	  (CML	  and	  MDAL)	  markers	  in	  both	  tissues,	  except	  for	  CEL	   in	   SKM	  which	   also	   showed	   a	   trend	   to	   decrease	   that	   did	   not	   reach	   statistical	  significance.	   Aging	   is	   known	   to	   increase	   protein	   oxidation	   in	   association	   with	   a	  functional	  decline	  of	  proteasome	  activity	  (48)	  whereas	  decreases	  in	  protein	  oxidation	  and	   increases	   in	   the	   catabolism	   of	   modified	   proteins	   have	   been	   described	   in	  experimental	  modifications	   that	   extend	   longevity,	   like	   dietary	   restriction	   (49)	   and	  methionine	   restriction	   (50,	   33)	   even	   when	   applied	   to	   old	   animals	   (51).	   The	  decreased	   fatty	  acid	  unsaturation	  degree	  most	   likely	   leads	   to	  a	   lower	   lipid-­‐derived	  secondary	  free	  radical	  formation,	  decreased	  specific	  protein	  oxidation	  and	  damage	  to	  other	   macromolecules	   (52)	   which	   was	   reflected,	   in	   our	   case,	   in	   the	   decrease	   in	  protein	  oxidation,	  glycoxidation	  and	  lipoxidation,	  as	  well	  as,	  in	  the	  case	  of	  the	  heart,	  mtDNA	  oxidative	  damage.	  	  The	  molecular	  mechanism	   suggested	   to	   explain	   these	   changes	   could	   be	   the	  following:	   binding	   of	   hormones	   and	   neurotransmitters	   to	   β-­‐adrenergic	   receptors	  activates	  adenylate	  cyclase	  (AC)	  increasing	  cyclic	  adenosine	  monophosphate	  (cAMP)	  and	  then	  protein	  kinase	  A	  (PKA).	  PKA	  inhibits	  Raf-­‐1,	  which,	  in	  turn,	  stimulates	  p-­‐MEK	  and	  p-­‐ERK.	  p-­‐ERK	  enters	  the	  nucleus,	  where	  it	  can	  modify	  gene	  expression	  through	  the	  action	  of	  many	  different	  molecules.	  Because	  AC	  stimulates	  PKA,	  and	  PKA	  inhibits	  Raf-­‐1,	  an	  increase	  in	  the	  Raf/MEK/ERK	  pathway	  is	  expected	  when	  AC	  is	  lacking	  or	  β-­‐adrenergic	  receptors	  are	  blocked.	  In	  agreement	  with	  this,	  an	  increase	  in	  p-­‐MEK	  and	  p-­‐ERK	  was	   observed	   in	   tissues	   of	   AC5KO	  mice,	   including	   the	   heart	   (1).	   The	   same	  happens	   in	   our	   pharmacological	   model	   of	   β-­‐adrenergic	   blockade	   by	   atenolol,	   in	  which	  p-­‐ERK	  levels	  were	  increased	  both	  at	  short-­‐term	  in	  the	  mice	  heart	  (2),	  as	  well	  as	  in	  the	  present	  study	  after	  long-­‐life	  AT	  treatment	  in	  heart	  and	  SKM	  mitochondria.	  This	   protein	   can	   enter	   the	   nucleus	   and	   activate	   different	   transcription	   factors,	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modifying	   genes	   related	   to	   oxidative	   stress,	   including	   genes	   coding	   for	   desaturase	  and	  elongase	  enzymes,	  as	  well	  as	  those	  controlling	  peroxisomal	  β-­‐oxidation,	  and	  are	  rate	   limiting	   for	   the	   synthesis	   of	   the	   highly	   peroxidizable	   22:6n-­‐3	   FA.	   Lower	  desaturase/elongase/peroxisomal	  β-­‐oxidation	  activities	  induced	  by	  the	  AT-­‐blockade	  (via	   low	   AC	   and	   high	   p-­‐ERK)	   would	   decrease	   22:6-­‐n3	   formation	   from	   its	   less	  unsaturated	  18:3n-­‐3	  dietary	  precursor.	  Concerning	   cellular	   signaling,	   AMPK	   responds	   to	   high	   intracellular	   levels	   of	  AMP,	   and	   activates	   (besides	   others)	   the	   expression	   of	   SIRT1	   (Silent	   information	  regulator	   1)	   (53).	   SIRT1	   regulates	   energy	   metabolism,	   cell	   apoptosis,	   cell	  proliferation	  and	  inflammation,	  as	  well	  as	  stress	  resistance	  by	  means	  of	  FOXO,	  p53	  and	   NF-­‐B	   signaling,	   increasing	   the	   intracellular	   concentration	   of	   NAD+.	   SIRT1	   is	  increased	   in	   caloric	   restriction	   (life-­‐extending)	   models,	   and	   can	   activate	   cellular	  stress	   resistance,	   playing	   an	   anti-­‐aging	   role	   (54).	   In	   our	   study,	   SIRT1	   levels	   were	  higher	  after	  the	  atenolol	  treatment	  in	  the	  heart,	  which	  indicates	  that	  the	  blocking	  of	  AC	  inactivates	  the	  AMPc.	  That	  would	  increase	  SIRT1	  expression	  through	  the	  ensuing	  changes	  in	  intracellular	  levels	  of	  AMP	  then	  of	  AMPK.	  Nrf2	   is	   the	   “master	   regulator”	   of	   the	   antioxidant	   response	   modulating	   the	  expression	  of	  many	  several	  antioxidant-­‐codifying	  genes	  (55),	  and	  TFAM	  is	  a	  regulator	  of	  mtDNA	  transcription,	  whose	  lack	  leads	  to	  severe	  respiratory	  chain	  deficiency	  (56).	  Since	   it	   is	   now	   well	   known	   that	   long-­‐lived	   animals	   have	   lower	   tissue	   levels	   of	  antioxidant	  enzymes	  and	  other	  endogenous	  antioxidants	  (57)	  and	   less	  endogenous	  DNA	   base	   excision	   repair	   (BER)	   activity	   (58),	   which	   are	   secondary	   events	   to	   the	  lower	  rate	  of	  mtROSp	  of	  long-­‐lived	  animal	  species	  (59,	  37),	  it	  is	  not	  strange	  that	  Nrf2	  and	  TFAM	  were	  decreased	  after	  atenolol	  treatment.	  Finally,	   although	   our	   results	   show	   an	   improvement	   in	   parameters	   related	  with	  longevity,	  a	  low	  DBI,	  PI,	  protein	  oxidation	  and	  lipoxidation	  in	  mitochondria	  from	  both	   tissues,	   and	   in	  mtDNA	   oxidative	   damage	   (in	   the	   case	   of	   heart),	   this	   was	   not	  enough	  to	  increase	  longevity,	  as	  it	  is	  evident	  form	  the	  survival	  curves	  finally	  obtained,	  since	   atenolol	   treated	  mice	   did	   not	   live	   longer	   than	   the	   control	   animals.	   Although	  mean	  life	  span	  was	  similar	  in	  both	  groups,	  only	  at	  the	  end	  of	  the	  life	  span	  and	  in	  very	  old	   animals	   (equivalent	   to	   70-­‐80	   years	   old	   humans)	   survival	   was	   somewhat	  decreased	  after	  long-­‐term	  treatment	  with	  atenolol.	  This	  can	  be	  due	  to	  a	  deleterious	  secondary	  effect	  of	   the	  drug.	  All	  β-­‐blockers	  act	  by	  decreasing	  blood	  pressure/heart	  rate	  (60),	  and	  that	  is	  known	  to	  be	  advantageous	  for	  coronary	  disease	  patients,	  or	  for	  those	   surviving	   after	   heart	   attacks	   or	   other	   serious	   cardiovascular	   illnesses.	  However,	   recent	   meta-­‐analyses	   in	   humans	   are	   suggesting	   that	   in	   the	   case	   of	   old	  hypertensive	  patient’s	  atenolol	  can	  decrease	  instead	  of	  increase	  survival	  (61).	  When	  old	  patients	   are	   treated	  with	  β-­‐blockers	   (atenolol	   is	  used	   in	   around	  75%	  of	   cases)	  rigid	   arteries	   typical	   of	   old	   people	   can	   result	   in	   sporadically	   too	   low	   diastolic	   or	  systolic	   blood	  pressures,	  which,	   together	  with	   the	   aged	  myocardium	  of	   old	   people	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can	   increase	   sudden	   cardiac	   death	   and	   thus	   mortality.	   It	   seems	   that	   the	   most	  important	  secondary	  effect	  of	  atenolol	   is	   the	  strongly	  decrease	   in	  heart	   rate	   that	   it	  induces	   (62,	  63).	  The	  meta	  analyses	  recently	  performed	   in	  humans	  agree	  with	  our	  results	   in	  mice,	  because	  we	  did	  not	   see	  any	  differences	   in	  blood	  pressure	  or	  heart	  rate	   when	   measured	   at	   18	   months	   of	   age,	   whereas	   heart	   rate	   was	   strongly	   and	  significantly	  decreased	  in	  the	  atenolol	  group	  at	  35	  months	  of	  age	  (499	  mmHg	  in	  Old	  AT	  compared	   to	  674	  mmHg	   in	  Old	   controls).	  We	  believe	   that	  our	   results	   are	  most	  important	   concerning	   future	   cardiologic	   treatments	   in	   humans	   since	   there	   are	  available	  antihypertensive	  drugs	  alternative	  to	  atenolol,	  and	  they	  constitute	  the	  first	  study	  of	  the	  long-­‐life	  effects	  of	  atenolol	  in	  a	  large	  population	  of	  healthy	  mammal.	  
5.	  CONCLUSION	  1.-­‐	  The	  long-­‐life	  treatment	  with	  the	  β-­‐blocker	  atenolol	  in	  drinking	  water	  of	  a	  large	  population	  of	  mice	  strongly	  decreases	  the	  degree	  of	  fatty	  acid	  unsaturation	  of	  skeletal	   muscle	   and	   mitochondrial	   membranes,	   the	   only	   parameter	   known,	   apart	  from	  a	  low	  rate	  of	  mitochondrial	  ROS	  generation,	  that	  correlates	  with	  longevity	  in	  the	  right	  way.	  	  2.-­‐	   That	   change	   seems	   to	   be	   due	   to	   a	   large	   extent	   to	   a	   decrease	   in	  desaturase/elongase/peroxisomal	  β-­‐oxidation	  activities,	  which	  are	   rate	   limiting	   for	  the	  synthesis	  of	  the	  highly	  unsaturated	  docosahexahenoic	  acid	  (22:6n-­‐3).	  This	  fatty	  acid	  is	  universally	  avoided	  in	  the	  tissue	  cellular	  membranes	  of	  long-­‐lived	  mammalian	  and	  bird	  species.	  3.-­‐	  Those	  decreases	  are	  due	  to	  β-­‐adrenergic	  blockade-­‐induced	  increases	  in	  p-­‐ERK	  signaling	  to	  the	  nucleus,	  and	  lead	  to	  strong	  decreases	  in	  oxidation,	  glycoxidation	  and	   lipoperoxidation	   of	  mitochondrial	   proteins,	   as	   well	   as	   in	   oxidative	   damage	   to	  mtDNA	  (in	  the	  case	  of	  heart	  tissue).	  4.-­‐	   These	  beneficial	   changes	  were	  not	   translated	   into	   increased	   (maximum)	  longevity	   most	   likely	   due	   to	   a	   secondary	   detrimental	   effect	   of	   the	   drug	   on	   heart	  frequency,	   and	   likely	   eventual	   falls	   in	   arterial	   pressure,	   only	   evident	   in	   very	   old	  animals,	  whereas	  the	  mean	  life	  span	  was	  not	  altered.	  These	  effects	  are	  most	  relevant	  for	  consideration	  of	  possible	  detrimental	  effects	  of	  atenolol,	  recently	  detected	  (meta-­‐analyses	  from	  2008	  on)	  only	  in	  old	  hypertensive	  human	  subjects.	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